London, UK; Brentwood, TN, US; 2 June 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today announces that
preliminary results of a phase 1 clinical study of ProlarixTM will be
presented at the American Society of Clinical Oncology (ASCO) Annual
Meeting in Chicago, USA, at 12 midday local time on Monday 2 June. The
clinical study was conducted by Cancer Research UK and Dr. Debashis
Sarker of the Royal Marsden Hospital, London will be presenting.
